Ausgabe 2/2011
Inhalt (34 Artikel)
Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review
Manon J. Pepels, Johanna H. M. J. Vestjens, Maaike de Boer, Marjolein Smidt, Paul J. van Diest, George F. Borm, Vivianne C. G. Tjan-Heijnen
Soy isoflavones consumption and risk of breast cancer incidence or recurrence: a meta-analysis of prospective studies
Jia-Yi Dong, Li-Qiang Qin
Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation
Michelle D. Sluiter, Elizabeth J. van Rensburg
The β2-adrenergic receptor and Her2 comprise a positive feedback loop in human breast cancer cells
Ming Shi, Dan Liu, Huijun Duan, Lu Qian, Lina Wang, Lijia Niu, Huipeng Zhang, Zheng Yong, Zehui Gong, Lun Song, Ming Yu, Meiru Hu, Qing Xia, Beifen Shen, Ning Guo
The PHSCN dendrimer as a more potent inhibitor of human breast cancer cell invasion, extravasation, and lung colony formation
Hongren Yao, Donna M. Veine, Kevin S. Fay, Evan D. Staszewski, Zhao-Zhu Zeng, Donna L. Livant
Stimulation of retinoic acid-induced functional sodium iodide symporter (NIS) expression and cytotoxicity of 131I by carbamazepine in breast cancer cells
Michael J. Willhauck, Dennis J. O`Kane, Nathalie Wunderlich, Burkhard Göke, Christine Spitzweg
Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer
E. A. Reijm, M. P. H. M. Jansen, K. Ruigrok-Ritstier, I. L. van Staveren, M. P. Look, M. E. Meijer van Gelder, A. M. Sieuwerts, S. Sleijfer, J. A. Foekens, E. M. J. J. Berns
High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer
Özcan Met, Eva Balslev, Henrik Flyger, Inge Marie Svane
Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors
Yayun Liang, Cynthia Besch-Williford, Indira Benakanakere, Philip E. Thorpe, Salman M. Hyder
Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis
Sirkku Pollari, Sanna-Maria Käkönen, Henrik Edgren, Maija Wolf, Pekka Kohonen, Henri Sara, Theresa Guise, Matthias Nees, Olli Kallioniemi
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials
Joanne L. Blum, Joseph Kohles, Edward McKenna, Nana Scotto, Sylvia Hu, Dawn Odom, James A. Kaye, Stefan Glück
The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer
G. J. van Londen, S. Perera, K. Vujevich, P. Rastogi, B. Lembersky, A. Brufsky, V. Vogel, S. L. Greenspan
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Guy Jerusalem, Angelica Fasolo, Veronique Dieras, Fatima Cardoso, Jonas Bergh, Luc Vittori, Yufen Zhang, Cristian Massacesi, Tarek Sahmoud, Luca Gianni
Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer
Barbro K. Linderholm, Henrik Hellborg, Ulla Johansson, Lambert Skoog, Janne Lehtiö
Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis
Weiguang Yuan, Lidan Xu, Wangyang Chen, Lihong Wang, Zhenkun Fu, Da Pang, Dianjun Li
Lack of association between ATM C.1066-6T > G mutation and breast cancer risk: a meta-analysis of 8,831 cases and 4,957 controls
Hong Ding, Chen Mao, Shui-Ming Li, Qu Liu, Lin Lin, Qing Chen
A functional −77T>C polymorphism in XRCC1 is associated with risk of breast cancer
Li Liu, Peng Yuan, Li Liu, Chen Wu, Xiaomin Zhang, Huan Guo, Rong Zhong, Yihua Xu, Jing Wu, Shengyu Duan, Rui Rui, Tangchun Wu, Shaofa Nie, Xiaoping Miao, Dongxin Lin
VEGF 936C>T polymorphism and breast cancer risk: evidence from 5,729 cases and 5,868 controls
Dongying Gu, Meilin Wang
Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen
Nava Siegelmann-Danieli, Daniel Kurnik, Yossi Lomnicky, Janet Vesterman-Landes, Itzhak Katzir, Martin Bialik, Ronen Loebstein
Cadmium concentration in biological media of breast cancer patients
Loreta Strumylaite, Algirdas Bogusevicius, Olegas Abdrachmanovas, Dale Baranauskiene, Rima Kregzdyte, Darius Pranys, Lina Poskiene
Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women’s Healthy Eating and Living Study
Cynthia A. Thomson, Cheryl L. Rock, Patricia A. Thompson, Bette J. Caan, Ellen Cussler, Shirley W. Flatt, John P. Pierce
RAD51 135G>C polymorphism and breast cancer risk: a meta-analysis
Guo-Wu Zhou, Jia Hu, Xu-Dong Peng, Qiang Li
Association between two polymorphisms of ABCB1 and breast cancer risk in the current studies: a meta-analysis
Pei-Hua Lu, Mu-Xin Wei, Jie Yang, Xiao Liu, Guo-Qing Tao, Wei Shen, Min-Bin Chen
Relationship between diabetes and risk of second primary contralateral breast cancer
Christopher I. Li, Janet R. Daling, Mei-Tzu C. Tang, Kathleen E. Malone
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
Ulla Wilking, Eva Karlsson, Lambert Skoog, Thomas Hatschek, Elisabet Lidbrink, Goran Elmberger, Hemming Johansson, Linda Lindström, Jonas Bergh
Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk
Christina Justenhoven, Elke Schaeffeler, Stefan Winter, Christian Baisch, Ute Hamann, Volker Harth, Sylvia Rabstein, Anne Spickenheuer, Beate Pesch, Thomas Brüning, Yon-Dschun Ko, Matthias Schwab, Hiltrud Brauch
The association between two polymorphisms in pre-miRNAs and breast cancer risk: a meta-analysis
Lin-Bo Gao, Peng Bai, Xin-Min Pan, Jing Jia, Li-Juan Li, Wei-Bo Liang, Ming Tang, Lu-Shun Zhang, Yong-Gang Wei, Lin Zhang
Risk of aggressive breast cancer in women of Han nationality carrying TGFB1 rs1982073 C allele and FGFR2 rs1219648 G allele in North China
Xiao-Hui Chen, Xiao-Qing Li, Ying Chen, Yu-Mei Feng
Individual responses to chemotherapy-induced oxidative stress
Dora Il’yasova, Kelly Kennedy, Ivan Spasojevic, Frances Wang, Adviye A. Tolun, Karel Base, Sarah P. Young, P. Kelly Marcom, Jeffrey Marks, David S. Millington, Mark W. Dewhirst
A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas
Talia Donenberg, John Lunn, DuVaughn Curling, Theodore Turnquest, Elisa Krill-Jackson, Robert Royer, Steven A. Narod, Judith Hurley
Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility was not credible: appraisal of a recent meta-analysis
Pei-Hua Lu, Xiu-Feng Huang
Need for clarification of results in the recent meta-analysis about SULT1A1 codon 213 polymorphism and breast cancer risk
Pei-Hua Lu, Mu-Xin Wei, Chen Li, Xiao Liu, Min-Bin Chen
No significant association results obtained from significant association evidence: the ongoing uncertainty of TP53 codon 72 polymorphism and breast cancer risk
Pei-Hua Lu, Guo-Qing Tao, Xiao Liu, Chen Li, Mu-Xin Wei